New blood test shows promise for detecting ALS early

Credibility

Interest

Share:2 min read

Key Takeaway

A blood test reading tiny DNA pieces can spot most ALS cases and may help predict how fast the disease will get worse.

What They Found

Researchers looked at small bits of DNA that float in the blood (called cell-free DNA, like crumbs from different cells) to find chemical tags called methylation that can change with disease. They compared people with ALS, people with a genetic ALS risk (C9orf72), carriers who don’t have symptoms yet, and people without disease. The team found many genes with different methylation patterns in people with ALS, including genes already linked to the illness. By combining several of these changes into a single signature, the test correctly separated ALS from non-ALS about 91% of the time on average and found around 70% of ALS cases while rarely flagging healthy people. They also found some methylation changes that matched how fast people worsened and matched a known test in spinal fluid (neurofilament) that signals nerve damage.

Who Should Care and Why

People with ALS and their caregivers should care because this approach points toward a simple blood test that might help confirm a diagnosis faster than some current methods. Family members who carry an ALS gene change (like C9orf72) might use this kind of test in the future to watch for early signs before symptoms start, similar to checking a warning light on a car. Doctors and clinics could use a blood-based marker to track disease speed or treatment effect without always needing spinal taps, which are more invasive. Researchers can build on this to make tests that are easier to use in clinic visits, helping with decisions about care and planning. Overall, it could mean fewer delays and clearer information about how ALS is progressing, which matters for daily planning and treatment choices.

Important Considerations

The study was small, with only a few dozen people, so the results need confirmation in larger groups before the test can be used in clinics. The test spotted about 70% of ALS cases in this study, so a negative result wouldn’t fully rule out ALS — it’s not perfect yet. Also, some findings came from people with a specific genetic form of ALS, so the test may work differently depending on the person’s disease type or other health factors.

AI-generated summary — for informational purposes only, not medical advice

Categories:

Early Research MS Diagnostics MS Progression

Article Topics:

BiomarkersEpigeneticsGeneticsNeurodegenerationNeuroscience

Whether you’ve recently been diagnosed with Multiple Sclerosis (MS) or are seeking to broaden your understanding of this complex, neurodegenerative disease, navigating the latest research can feel overwhelming. Studies published in respected medical journals like The Journal of clinical investigation often range from early-stage, exploratory work to advanced clinical trials. These evidence-based findings help shape new disease-modifying therapies, guide symptom management techniques, and deepen our knowledge of MS progression.

However, not all research is created equal. Some clinical research studies may have smaller sample sizes, evolving methodologies, or limitations that warrant careful interpretation. For a more comprehensive, accurate understanding, we recommend reviewing the original source material—accessible via the More Details section above—and consulting with healthcare professionals who specialize in MS care.

By presenting a wide range of MS-focused studies—spanning cutting-edge treatments, emerging therapies, and established best practices—we aim to empower patients, caregivers, and clinicians to stay informed and make well-informed decisions when managing Multiple Sclerosis.

Back to News